English
简体中文
Total: £ 56.28
Published Date: 2026-03-20 | Pages: 105 | Tables: 107 | Pharma & Healthcare
The global HIV Prevention Drug market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on HIV Prevention Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for HIV Prevention Drug is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for HIV Prevention Drug is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of HIV Prevention Drug include Gilead Sciences, ViiV Healthcare, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global HIV Prevention Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HIV Prevention Drug. The HIV Prevention Drug market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global HIV Prevention Drug market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist HIV Prevention Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Segment by Type
Lenacapavir
Cabotegravir
by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for HIV Prevention Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines HIV Prevention Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 HIV Prevention Drug Market Overview
1.1 Product Definition
1.2 HIV Prevention Drug by Type
1.2.1 Global HIV Prevention Drug Market Value by Type: 2025 vs 2032
1.2.2 Lenacapavir
1.2.3 Cabotegravir
1.3 HIV Prevention Drug by Application
1.3.1 Global HIV Prevention Drug Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global HIV Prevention Drug Market Size Estimates and Forecasts
1.4.1 Global HIV Prevention Drug Revenue 2021–2032
1.4.2 Global HIV Prevention Drug Sales 2021–2032
1.4.3 Global HIV Prevention Drug Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 HIV Prevention Drug Market Competition by Manufacturers
2.1 Global HIV Prevention Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global HIV Prevention Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global HIV Prevention Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of HIV Prevention Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of HIV Prevention Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of HIV Prevention Drug, Product Types and Applications
2.7 Global Key Manufacturers of HIV Prevention Drug, Date of Entry into the Industry
2.8 Global HIV Prevention Drug Market Competitive Situation and Trends
2.8.1 Global HIV Prevention Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global HIV Prevention Drug Players Market Share by Revenue
2.8.3 Global HIV Prevention Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HIV Prevention Drug Market Scenario by Region
3.1 Global HIV Prevention Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global HIV Prevention Drug Sales by Region: 2021–2032
3.2.1 Global HIV Prevention Drug Sales by Region: 2021–2026
3.2.2 Global HIV Prevention Drug Sales by Region: 2027–2032
3.3 Global HIV Prevention Drug Revenue by Region: 2021–2032
3.3.1 Global HIV Prevention Drug Revenue by Region: 2021–2026
3.3.2 Global HIV Prevention Drug Revenue by Region: 2027–2032
3.4 North America HIV Prevention Drug Market Facts & Figures by Country
3.4.1 North America HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America HIV Prevention Drug Sales by Country (2021–2032)
3.4.3 North America HIV Prevention Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe HIV Prevention Drug Market Facts & Figures by Country
3.5.1 Europe HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe HIV Prevention Drug Sales by Country (2021–2032)
3.5.3 Europe HIV Prevention Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV Prevention Drug Market Facts & Figures by Region
3.6.1 Asia Pacific HIV Prevention Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific HIV Prevention Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific HIV Prevention Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HIV Prevention Drug Market Facts & Figures by Country
3.7.1 Latin America HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America HIV Prevention Drug Sales by Country (2021–2032)
3.7.3 Latin America HIV Prevention Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HIV Prevention Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa HIV Prevention Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa HIV Prevention Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HIV Prevention Drug Sales by Type (2021–2032)
4.1.1 Global HIV Prevention Drug Sales by Type (2021–2026)
4.1.2 Global HIV Prevention Drug Sales by Type (2027–2032)
4.1.3 Global HIV Prevention Drug Sales Market Share by Type (2021–2032)
4.2 Global HIV Prevention Drug Revenue by Type (2021–2032)
4.2.1 Global HIV Prevention Drug Revenue by Type (2021–2026)
4.2.2 Global HIV Prevention Drug Revenue by Type (2027–2032)
4.2.3 Global HIV Prevention Drug Revenue Market Share by Type (2021–2032)
4.3 Global HIV Prevention Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global HIV Prevention Drug Sales by Application (2021–2032)
5.1.1 Global HIV Prevention Drug Sales by Application (2021–2026)
5.1.2 Global HIV Prevention Drug Sales by Application (2027–2032)
5.1.3 Global HIV Prevention Drug Sales Market Share by Application (2021–2032)
5.2 Global HIV Prevention Drug Revenue by Application (2021–2032)
5.2.1 Global HIV Prevention Drug Revenue by Application (2021–2026)
5.2.2 Global HIV Prevention Drug Revenue by Application (2027–2032)
5.2.3 Global HIV Prevention Drug Revenue Market Share by Application (2021–2032)
5.3 Global HIV Prevention Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences HIV Prevention Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences HIV Prevention Drug Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare HIV Prevention Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 ViiV Healthcare HIV Prevention Drug Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV Prevention Drug Industry Chain Analysis
7.2 HIV Prevention Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV Prevention Drug Production Mode & Process Analysis
7.4 HIV Prevention Drug Sales and Marketing
7.4.1 HIV Prevention Drug Sales Channels
7.4.2 HIV Prevention Drug Distributors
7.5 HIV Prevention Drug Customer Analysis
8 HIV Prevention Drug Market Dynamics
8.1 HIV Prevention Drug Industry Trends
8.2 HIV Prevention Drug Market Drivers
8.3 HIV Prevention Drug Market Challenges
8.4 HIV Prevention Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global HIV Prevention Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global HIV Prevention Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global HIV Prevention Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global HIV Prevention Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global HIV Prevention Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global HIV Prevention Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global HIV Prevention Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market HIV Prevention Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of HIV Prevention Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of HIV Prevention Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of HIV Prevention Drug, Product Types and Applications
Table 12. Global Key Manufacturers of HIV Prevention Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global HIV Prevention Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on HIV Prevention Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global HIV Prevention Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global HIV Prevention Drug Sales by Region (K Units), 2021–2026
Table 18. Global HIV Prevention Drug Sales Market Share by Region (2021–2026)
Table 19. Global HIV Prevention Drug Sales by Region (K Units), 2027–2032
Table 20. Global HIV Prevention Drug Sales Market Share by Region (2027–2032)
Table 21. Global HIV Prevention Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global HIV Prevention Drug Revenue Market Share by Region (2021–2026)
Table 23. Global HIV Prevention Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global HIV Prevention Drug Revenue Market Share by Region (2027–2032)
Table 25. North America HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America HIV Prevention Drug Sales by Country (K Units), 2021–2026
Table 27. North America HIV Prevention Drug Sales by Country (K Units), 2027–2032
Table 28. North America HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe HIV Prevention Drug Sales by Country (K Units), 2021–2026
Table 32. Europe HIV Prevention Drug Sales by Country (K Units), 2027–2032
Table 33. Europe HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific HIV Prevention Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific HIV Prevention Drug Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific HIV Prevention Drug Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific HIV Prevention Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific HIV Prevention Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America HIV Prevention Drug Sales by Country (K Units), 2021–2026
Table 42. Latin America HIV Prevention Drug Sales by Country (K Units), 2027–2032
Table 43. Latin America HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa HIV Prevention Drug Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa HIV Prevention Drug Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global HIV Prevention Drug Sales (K Units) by Type (2021–2026)
Table 51. Global HIV Prevention Drug Sales (K Units) by Type (2027–2032)
Table 52. Global HIV Prevention Drug Sales Market Share by Type (2021–2026)
Table 53. Global HIV Prevention Drug Sales Market Share by Type (2027–2032)
Table 54. Global HIV Prevention Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global HIV Prevention Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global HIV Prevention Drug Revenue Market Share by Type (2021–2026)
Table 57. Global HIV Prevention Drug Revenue Market Share by Type (2027–2032)
Table 58. Global HIV Prevention Drug Price (US$/Unit) by Type (2021–2026)
Table 59. Global HIV Prevention Drug Price (US$/Unit) by Type (2027–2032)
Table 60. Global HIV Prevention Drug Sales (K Units) by Application (2021–2026)
Table 61. Global HIV Prevention Drug Sales (K Units) by Application (2027–2032)
Table 62. Global HIV Prevention Drug Sales Market Share by Application (2021–2026)
Table 63. Global HIV Prevention Drug Sales Market Share by Application (2027–2032)
Table 64. Global HIV Prevention Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global HIV Prevention Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global HIV Prevention Drug Revenue Market Share by Application (2021–2026)
Table 67. Global HIV Prevention Drug Revenue Market Share by Application (2027–2032)
Table 68. Global HIV Prevention Drug Price (US$/Unit) by Application (2021–2026)
Table 69. Global HIV Prevention Drug Price (US$/Unit) by Application (2027–2032)
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Gilead Sciences HIV Prevention Drug Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. ViiV Healthcare Company Information
Table 76. ViiV Healthcare Description and Business Overview
Table 77. ViiV Healthcare HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. ViiV Healthcare HIV Prevention Drug Product
Table 79. ViiV Healthcare Recent Developments/Updates
Table 80. Key Raw Materials Lists
Table 81. Raw Materials Key Suppliers Lists
Table 82. HIV Prevention Drug Distributors List
Table 83. HIV Prevention Drug Customers List
Table 84. HIV Prevention Drug Market Trends
Table 85. HIV Prevention Drug Market Drivers
Table 86. HIV Prevention Drug Market Challenges
Table 87. HIV Prevention Drug Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
Table 91. Authors List of This Report
List of Figures
Figure 1. Product Picture of HIV Prevention Drug
Figure 2. Global HIV Prevention Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global HIV Prevention Drug Market Share by Type: 2025 & 2032
Figure 4. Lenacapavir Product Picture
Figure 5. Cabotegravir Product Picture
Figure 6. Global HIV Prevention Drug Market Value by Application (US$ Million), 2021–2032
Figure 7. Global HIV Prevention Drug Market Share by Application: 2025 & 2032
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Global HIV Prevention Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global HIV Prevention Drug Market Size (US$ Million), 2021–2032
Figure 13. Global HIV Prevention Drug Sales (K Units), 2021–2032
Figure 14. Global HIV Prevention Drug Average Price (US$/Unit), 2021–2032
Figure 15. HIV Prevention Drug Report Years Considered
Figure 16. HIV Prevention Drug Sales Share by Manufacturers in 2025
Figure 17. Global HIV Prevention Drug Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global HIV Prevention Drug Players: Market Share by Revenue in HIV Prevention Drug in 2025
Figure 19. HIV Prevention Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global HIV Prevention Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America HIV Prevention Drug Sales Market Share by Country (2021–2032)
Figure 22. North America HIV Prevention Drug Revenue Market Share by Country (2021–2032)
Figure 23. United States HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe HIV Prevention Drug Sales Market Share by Country (2021–2032)
Figure 26. Europe HIV Prevention Drug Revenue Market Share by Country (2021–2032)
Figure 27. Germany HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific HIV Prevention Drug Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific HIV Prevention Drug Revenue Market Share by Region (2021–2032)
Figure 34. China HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America HIV Prevention Drug Sales Market Share by Country (2021–2032)
Figure 42. Latin America HIV Prevention Drug Revenue Market Share by Country (2021–2032)
Figure 43. Mexico HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa HIV Prevention Drug Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa HIV Prevention Drug Revenue Market Share by Country (2021–2032)
Figure 49. Turkey HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of HIV Prevention Drug by Type (2021–2032)
Figure 53. Global Revenue Market Share of HIV Prevention Drug by Type (2021–2032)
Figure 54. Global HIV Prevention Drug Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of HIV Prevention Drug by Application (2021–2032)
Figure 56. Global Revenue Market Share of HIV Prevention Drug by Application (2021–2032)
Figure 57. Global HIV Prevention Drug Price (US$/Unit) by Application (2021–2032)
Figure 58. HIV Prevention Drug Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
